These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37728121)

  • 1. Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species.
    Jung E; Kraimps A; Dittmann S; Griesser T; Costafrolaz J; Mattenberger Y; Jurt S; Viollier PH; Sander P; Sievers S; Gademann K
    Chembiochem; 2023 Dec; 24(24):e202300570. PubMed ID: 37728121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
    Babakhani F; Seddon J; Sears P
    Antimicrob Agents Chemother; 2014 May; 58(5):2934-7. PubMed ID: 24550338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
    Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
    Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin jams
    Boyaci H; Chen J; Lilic M; Palka M; Mooney RA; Landick R; Darst SA; Campbell EA
    Elife; 2018 Feb; 7():. PubMed ID: 29480804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.
    Babakhani F; Gomez A; Robert N; Sears P
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4427-9. PubMed ID: 21709084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
    Allen CA; Babakhani F; Sears P; Nguyen L; Sorg JA
    Antimicrob Agents Chemother; 2013 Jan; 57(1):664-7. PubMed ID: 23147724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel fidaxomicin antibiotics through site-selective catalysis.
    Dailler D; Dorst A; Schäfle D; Sander P; Gademann K
    Commun Chem; 2021 May; 4(1):59. PubMed ID: 36697765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
    Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.
    Artsimovitch I; Seddon J; Sears P
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S127-31. PubMed ID: 22752861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dissection of RbpA-mediated regulation of fidaxomicin sensitivity in mycobacteria.
    Prusa J; Zhu DX; Flynn AJ; Jensen D; Ruiz Manzano A; Galburt EA; Stallings CL
    J Biol Chem; 2022 Apr; 298(4):101752. PubMed ID: 35189142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
    Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
    James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
    J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Oka D; Yamaya N; Kuno T; Asakawa Y; Shiragiku T; Chen L; Xue J; Mamuti A; Ye F; Sun J; Ohguro K; Miyamoto H; Uematsu Y; Inagaki K; Cheng JF; Matsumoto M
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activities of fidaxomicin.
    Goldstein EJ; Babakhani F; Citron DM
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S143-8. PubMed ID: 22752863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.